NCT06972732RecruitingPhase 4
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 15 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- First submitted
- 7 May 2025
- Start date
- 11 Jun 2025
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Diseases
- Type 2 diabetes
- NCT number
- NCT06972732
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 204
- From 11 Jun 2025 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study
Other illness
- Has severe renal and liver disorders
- Has type 1 diabetes
Other
- Those who are deemed ineligible to participate in the study by the investigator
Who the study is looking for
- Has voluntarily agreed to participate in this clinical trial.
- Adults over 19 years of age
- Diagnosed with type 2 diabetes
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Catholic University of Korea, Seoul ST. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.